secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001437749-24-031133
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx CEO resigns; Chairman Javitt takes interim CEO; shareholders approve reverse split
--------------------------------------------------------------------------------

- CEO Stephen Willard resigns effective Oct 7, 2024; Chairman Jonathan Javitt appointed interim CEO.
- Stockholders approved reverse stock split authorization (1:2 to 1:5) at board's discretion within one year.
- Stockholders approved issuance of shares upon redemption of convertible note and warrants to institutional investors.
- Company signed LOI to acquire an interventional psychiatry clinic; targeting $25M+ initial HOPE Therapeutics business and $100M+ revenue by next year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/0001437749-24-031133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/nrxp20241011_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer